Published on 24 October 2022
Description:
Amid political chaos, PharmaTimes looks across the vast pharmaverse in an attempt to make sense of the rapidly changing landscape. Our cover story reflects on the incredible HIV/AIDS story – how it emerged, what it is like to manage the condition, how those with a positive status no longer face a death sentence and what it is like growing old when you are HIV positive.
Categories:
PharmaTimes28 articles from this collection:
Cover
2 - PharmaTimes Marketer of the Year
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Healthcare
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: Clinical Trials
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-11 - HIV/AIDS: Won
12-13 - Cover Story: We've Come a Long Way
14-15 - Rare Diseases: Society’s ties
16-17 - Carers: The price of love
18-19 - AI: Cold comfort?
20 - Thought Leadership: Pharma chameleon
21 - SUSTAINABILITY: We are the robots
22-23 - Mental Health: Hearts and minds
24-26 - ABPI: We can see clearly now
27 - AI: The human condition
28 - ICON: True voices
29 - SAMEDAN
30 - Mental Health: Mind Craft
31 - Pharma Future: Do we focus enough on the well-being of members of promotional review teams?
32-33 - NHS: Life cycle
34-35 - Your moves
36-37 - Pharmatimes Awards: Unbelievable site
38 - SAMEDAN
39 - PHARMATIMES
40 - PMPS
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.